The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VRTX | -1.71% | +125.44% | +17.65% | +10,520% |
| S&P | +18.89% | +78.8% | +12.32% | +1,714% |
Vertex is in the business of discovering, developing, and commercializing small-molecule drugs for the treatment of serious genetic diseases including cystic fibrosis.
These two biotechs have a lot in common. Their differences are even more pronounced.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.23B | 11.8% |
| Gross Profit | $2.76B | 12.1% |
| Gross Margin | 85.56% | 0.2% |
| Market Cap | $115.03B | 10.9% |
| Market Cap / Employee | $17.97M | 0.0% |
| Employees | 6.4K | 4.9% |
| Net Income | $1.19B | 30.5% |
| EBITDA | $1.35B | 19.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.09B | 11.3% |
| Accounts Receivable | $2.05B | 27.6% |
| Inventory | 1.7K | 39.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.95B | 17.9% |
| Short Term Debt | $82.80M | -10.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 16.06% | 18.4% |
| Return On Invested Capital | 17.80% | -4.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $348.60M | -29.1% |
| Operating Free Cash Flow | $498.00M | -14.8% |
| Metric | Q1 2024 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 27.12 | 31.82 | 27.60 | 29.56 | - |
| Price to Book | 7.59 | 6.93 | 5.84 | 6.65 | 0.11% |
| Price to Sales | 11.39 | 10.12 | 8.60 | 9.62 | 0.69% |
| Price to Tangible Book Value | 8.59 | 7.64 | 6.41 | 7.29 | -3.75% |
| Price to Free Cash Flow TTM | 32.93 | 30.23 | 36.35 | - | |
| Enterprise Value to EBITDA | 114.88 | 89.96 | 72.40 | 82.40 | -7.14% |
| Free Cash Flow Yield | 3.0% | 3.3% | 2.8% | - | |
| Return on Equity | -5.6% | 22.8% | 22.3% | 22.5% | -815.25% |
| Total Debt | $1.65B | $1.53B | $1.83B | $2.04B | 16.38% |
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.
We examine three biotech companies' past performances and future outlooks.
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
